Unichem Gets Usfda Nod For Generic Medication

The Company Has Received Approval From The Us Food And Drug Administration (Usfda) To Market Its Product In The Strength Of 200 Mg, Unichem Laboratories Said In A Statement.Drug Firm Unichem Laboratories On Tuesday Said It Has Received Approval From The Us Health Regulator To Market Carbamazepine Tablets, An Anticonvulsant Drug, In The American Market. The Company Has Received Approval From The Us Food And Drug Administration (Usfda) To Market Its Product In The Strength Of 200 Mg, Unichem Laboratories Said In A Statement. The Mumbai-Based Drug Maker'S Product Is The Generic Version Of Novartis Pharmaceuticals Corp'S Tegretol Tablets Which Is Indicated For Use As An Anticonvulsant Drug And In The Treatment Of The Pain Associated With Trigeminal The Product Will Be Produced At The Company'S Goa Plant, Unichem Stated. Shares Of The Company Were Trading 4.33 Per Cent Up At Rs 297.25 Apiece On The Bse

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!